A news release from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on 22nd October reported that the latest edition in the EMCDDA Papers series is concerned with captagon and understanding the illegal market for the drug, and what is currently known about the captagon phenomenon in order to assist those working in the illicit drugs field who may need to respond to the issue. Captagon was originally the brand name for a medicinal product containing fenetylline (fenetylline was placed under international control in 1986) produced since the 1960s and serving licit markets in Europe and the Middle East. Sold in tablet form, it was prescribed as a treatment for conditions such as attention deficit disorder and narcolepsy, but it is no longer produced or used for therapeutic purposes. Traffickers started producing tablets containing other substances, especially amphetamine, which were then sold as ‘captagon’ on markets for stimulants in the Middle East – and it is reported to be a commonly used stimulant in the Middle East and seizures have been increasing in a number of Middle East countries (particularly Israel, Jordan and UAE). Production now seems to be largely in the Middle East.
The report is available at –